<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912389</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-100-3</org_study_id>
    <nct_id>NCT03912389</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC</brief_title>
  <acronym>DOMAJOR</acronym>
  <official_title>International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in Combination With Pemetrexed+Cisplatin/Carboplatin Compared to Placebo in Combination With Pemetrexed+Cisplatin/Carboplatin as First-Line Treatment of Subjects With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy&#xD;
      and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to&#xD;
      placebo in combination with pemetrexed+cisplatin/carboplatin in subjects with previously&#xD;
      untreated metastatic non-squamous NSCLC. The main hypothesis of the study is that BCD-100 in&#xD;
      combination with chemotherapy prolongs OS compared to placebo with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of randomization until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The time from the date of randomization until progression of disease according to RECIST 1.1 and iRECIST or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of the participants who have a Complete Response or a Partial Response as assessed by a blind independent central reviewer per RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of the participants who have a Complete Response, a Partial Response or a Stable Disease as assessed by a blind independent central reviewer per RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>1 year</time_frame>
    <description>TTR will be calculated from the randomization date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>DOR will be calculated from the moment of registration of response till event (disease progression or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Non-Squamous Non-Small Cell Neoplasm of Lung</condition>
  <arm_group>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-100 3 mg/kg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-100</intervention_name>
    <description>Anti-PD-1 monoclonal antibody, IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (or carboplatin)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has voluntarily agreed to participate by giving written informed consent for&#xD;
             the trial;&#xD;
&#xD;
          2. Patients ≥ 18 years of age on day of signing informed consent;&#xD;
&#xD;
          3. Previously untreated patients with histologically-confirmed stage IV (M1a/M1b/M1c-&#xD;
             AJCC 8th edition) non-squamous NSCLC;&#xD;
&#xD;
          4. Has not received prior systemic treatment for metastatic NSCLC;&#xD;
&#xD;
          5. The time from the completion of previous adjuvant/neoadjuvant treatment to metastatic&#xD;
             disease development is no less than 12 months;&#xD;
&#xD;
          6. Has a life expectancy of at least 12 weeks;&#xD;
&#xD;
          7. Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;&#xD;
&#xD;
          8. Has adequate organ function as defined by hematological laboratory values (absolute&#xD;
             neutrophil count ≥1.500/mcL, platelets ≥100.000/mcL, hemoglobin ≥9 g/dL ), renal&#xD;
             laboratory values (serum creatinine or calculated creatinine clearance &lt;1.5xULN or ≥60&#xD;
             mL/min for subjects with creatinine levels&gt;1.5x institutional ULN), and hepatic&#xD;
             laboratory values (serum total bilirubin &lt;1.5xULN, AST and ALT ≤2.5xULN, alkaline&#xD;
             phosphatase &lt;2.5xULN);&#xD;
&#xD;
          9. Agreement to newly obtained core or excisional biopsy of a tumor lesion not previously&#xD;
             irradiated for determination of PD-L1 status prior to randomization (if obtaining of&#xD;
             new sample is contraindicated or puts subject at unacceptable risks, then archival&#xD;
             tumor tissue sample must be available)&#xD;
&#xD;
         10. Measurable disease according to CT scan (RECIST 1.1 criteria) , confirmed by the local&#xD;
             assessment;&#xD;
&#xD;
         11. For subjects of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual inter-course) or use a contraceptive method with a failure rate of &lt; 1%&#xD;
             per year during the treatment period and for at least 6 months after administration of&#xD;
             the last dose of study drug; and 6 months after the last dose of platinum-based&#xD;
             chemotherapy, whichever is later. A woman is considered to be of childbearing&#xD;
             potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12&#xD;
             continuous months of amenorrhea with no identified cause other than menopause), and&#xD;
             has not undergone surgical sterilization (removal of ovaries, fallopian tubes, and/or&#xD;
             uterus). Examples of contraceptive methods with a failure rate of &lt; 1% per year&#xD;
             include but are not limited to bilateral tubal ligation and/or occlusion, male&#xD;
             sterilization, and intrauterine devices. The reliability of sexual abstinence should&#xD;
             be evaluated in relation to the duration of the clinical study and the preferred and&#xD;
             usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation,&#xD;
             symptothermal, or postovulation methods) and withdrawal are not acceptable methods of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has predominantly squamous cell histology NSCLC; Mixed tumors will be categorized by&#xD;
             the predominant cell type; if small cell elements are present, the subject is&#xD;
             ineligible.&#xD;
&#xD;
          2. Presence of EGFR mutation or ALK translocation;&#xD;
&#xD;
          3. Has received prior systemic cytotoxic chemotherapy/chemoradiotherapy for metastatic&#xD;
             disease;&#xD;
&#xD;
          4. Has received antineoplastic therapy with targeted or immunotherapeutic drugs&#xD;
             (including but not limited to EGFR inhibitors [e.g., erlotinib, gefitinib, cetuximab],&#xD;
             ALK inhibitors, PD-1/PD-L1/PD-L2/CTLA4, VEGF/VEGFR inhibitors) or it is expected to&#xD;
             require any other form of antineoplastic therapy while on study;&#xD;
&#xD;
          5. Completed radiation therapy within 14 days before the first dose of the study drug;&#xD;
&#xD;
          6. Received a live-virus vaccination within 30 days prior to the first study drug&#xD;
             administration;&#xD;
&#xD;
          7. Current treatment in another investigational device or drug study, or less than 28&#xD;
             days since ending treatment on another investigational device or drug study;&#xD;
&#xD;
          8. Had major surgery less than 28 days prior to the first dose of the study drug;&#xD;
&#xD;
          9. Evidence of severe or concomitant diseases/life-threatening complications of the main&#xD;
             condition (including but not limited to massive pleural, pericardial, or peritoneal&#xD;
             effusion that requires medical intervention , pulmonary lymphangitis, hemorrhage,&#xD;
             organ perforation) at the signing of the informed consent;&#xD;
&#xD;
         10. Concomitant diseases or conditions which pose a risk of AE development during study&#xD;
             treatment:&#xD;
&#xD;
               1. uncontrolled hypertension, defined as systolic &gt; 150 mm Hg or diastolic &gt; 90 mm&#xD;
                  Hg; define diagnosis of hypertension&#xD;
&#xD;
               2. stable angina functional class III-IV;&#xD;
&#xD;
               3. unstable angina or myocardial infarction less than 6 months prior to&#xD;
                  randomization;&#xD;
&#xD;
               4. NYHA Grade III-IV congestive heart failure;&#xD;
&#xD;
               5. serious cardiac arrhythmia requiring medication (subjects with asymptomatic&#xD;
                  atrial fibrillation can be enrolled if controlled ventricular rate);&#xD;
&#xD;
               6. atopic asthma, Stage III-IV COPD, angioedema;&#xD;
&#xD;
               7. severe respiratory failure;&#xD;
&#xD;
               8. any other diseases which pose unacceptable risk of AE development during study&#xD;
                  treatment in Investigator's opinion;&#xD;
&#xD;
         11. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis ;&#xD;
&#xD;
         12. Active or known or suspected autoimmune disease (subjects with Type 1 diabetes&#xD;
             mellitus, hypothyroidism only requiring hormone replacement, or skin disorders&#xD;
             (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to&#xD;
             enroll).&#xD;
&#xD;
         13. Has clinically active diverticulitis, intra-abdominal abscess, GI obstruction,&#xD;
             abdominal carcinomatosis;&#xD;
&#xD;
         14. Has interstitial lung disease or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoids to assist with management. Lymphangitic spread of the&#xD;
             NSCLC is not exclusionary;&#xD;
&#xD;
         15. Condition requiring systemic treatment with either corticosteroids or other&#xD;
             immunosuppressive medications in past 2 years;&#xD;
&#xD;
         16. Is unable or unwilling to take folic acid or vitamin B12 supplementation;&#xD;
&#xD;
         17. Known history of prior malignancy except if participant has undergone potentially&#xD;
             curative therapy with no evidence of that disease recurrence for 2 years since&#xD;
             initiation of that therapy, except for successful definitive resection of basal cell&#xD;
             carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the&#xD;
             skin, in situ cervical cancer, or other in situ cancers;&#xD;
&#xD;
         18. Pre-existing clinically significant (≥ grade 2) peripheral neuropathy or hearing&#xD;
             impairment;&#xD;
&#xD;
         19. Any conditions or circumstances that limit subject's ability to comply with protocol&#xD;
             requirements;&#xD;
&#xD;
         20. Active hepatitis B, hepatitis С or HIV in anamnesis;&#xD;
&#xD;
         21. Acute infection or reactivation of chronic infection or systemic antibiotics use less&#xD;
             than 14 days prior to first dose of the study drug; Severe infections within 28 days&#xD;
             prior to the first study drug administration.&#xD;
&#xD;
         22. Significant adverse reactions of previous therapy excluding chronic and/or&#xD;
             irreversible events which cannot affect study drug safety evaluation (e.g. alopecia);&#xD;
&#xD;
         23. Known hypersensitivity or allergy to drugs containing Chinese hamster (CHO) ovary&#xD;
             cells or history of severe allergic, anaphylactic, or other hypersensitivity reactions&#xD;
             to chimeric or humanized antibodies or fusion proteins, to pemetrexed, carboplatin,&#xD;
             cisplatin, BCD-100 or any of their excipients;&#xD;
&#xD;
         24. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulia N Linkova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Clinical Development Department, BIOCAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fedor B Krykov, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey N Fogt, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Hospital Liberec</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Sochor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Bartek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiscan Pardubice - Radiology Center</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Vanasek, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>High technology Hospital Medcenter</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamta Makharadze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acad. F.Todua Medical center &quot;Research institute of Clinical Medicine&quot;</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Melkadze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Centre, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Gogishvili, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Personalized Medicine Ltd.</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Tavartkiladze, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LEPL First University Clinic of Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nana Chikhladze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Korányi Institute of Pulmonology IV. Pulmonology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisztina BOGOS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Pulmonology Clinic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika MÜLLER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mátra Health Institution Pulmonology</name>
      <address>
        <city>Mátraháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>László URBÁN, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Medisprof S.R.L</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udrea A Anghel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Radiotherapy Center Cluj S.R.L</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manolescu A Alexandru, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Sfantul Nectarie&quot; Oncology Center SRL</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schenker Michael, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Oncolab S.R.L</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lungulescu Stefan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Pelican Impex S.R.L</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puscas I Adriana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical Municipal Hospital Timisoara - Medical Oncology Clinic</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curescu Petra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Oncocenter Clinical Oncology S.R.L</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scheusan R Ioana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Oncomed S.R.L</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Segarceanu N Alina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C Salvosan Ciobanca S.R.</name>
      <address>
        <city>Zalau</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Papp Margareta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangel'sk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina N Nechaeva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 5</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis A Tancyirev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan A Zukov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital No. 62</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniil L Stroyakovsky, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail V Dvorkin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;New Clinic&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery M Chistyakov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AV Medical Group</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timur T Andabekov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC BioEk</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Odintsova, MD</last_name>
      <phone>+78129452232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay V Kislov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jacob's Hospital</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozef Chovanec, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Komarno a.s.</name>
      <address>
        <city>Komarno</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Rosinska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Slovak Oncology Institute</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Andrasina, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital with Policlinic of Stefan Kukura</name>
      <address>
        <city>Michalovce</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Hermanova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital with Policlinic</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavol Demo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Outpatient Oncology Clinic</name>
      <address>
        <city>Partizanske</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Szabova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital of J.A. Reiman</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslava Leskova, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

